Liraglutide add-on to insulin degludec plus metformin vs addition of a single dose of insulin aspart to the largest meal in patients with Type 2 diabetes

被引：0
|
作者：
Russell-Jones, D. [1 ,2 ]
Mathieu, C. [3 ]
Rodbard, H. W. [4 ]
Cariou, B. [5 ]
Handelsman, Y. [6 ]
Philis-Tsimikas, A. [7 ]
Francisco, A. M. Ocampo [8 ]
Rana, A. [8 ]
Zinman, B. [9 ]
机构：
[1] Royal Surrey Cty Hosp, Guildford, Surrey, England
[2] Univ Surrey, Guildford GU2 5XH, Surrey, England
[3] Katholieke Univ Leuven, UZ Gasthuisberg, Louvain, Belgium
[4] Endocrine & Metab Consultants, Rockville, MD USA
[5] CHU Nantes, Inst Thorax, Clin Endocrinol, F-44035 Nantes 01, France
[6] Metab Inst Amer, Tarzana, CA USA
[7] Scripps Hlth, Scripps Whittier Diabet Inst, La Jolla, CA USA
[8] Novo Nordisk AS, Soborg, Denmark
[9] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada
来源：
DIABETIC MEDICINE | 2014年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [21] Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
    Gough, Stephen C. L.
    Jain, Rajeev
    Woo, Vincent C.
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (01) : 7 - 19
  • [22] Treatment intensification with insulin degludec improves glycaemic control in patients with Type 2 diabetes treated with liraglutide and metformin
    Kumar, S.
    Aroda, V.
    Bailey, T.
    Cariou, B.
    Leiter, L.
    Raskin, P.
    Zacho, J.
    Philis-Tsimikas, A.
    DIABETIC MEDICINE, 2015, 32 : 66 - 66
  • [23] Empagliflozin as add-on to metformin plus sulfonylurea in patients with Type 2 diabetes
    Haering, H. U.
    Merker, L.
    Christiansen, A. Vedel
    Roux, F.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 89 - 89
  • [24] Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes
    Haering, Hans-Ulrich
    Merker, Ludwig
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2015, 110 (01) : 82 - 90
  • [25] Efficacy and safety of linagliptin as add-on therapy to basal insulin and metformin in patients with type 2 diabetes
    Lee, J.
    Duran-Garcia, S.
    Yki-Jarvinen, H.
    Rosenstock, J.
    Hehnke, U.
    Thiemann, S.
    Patel, S.
    Woerle, H. -J.
    DIABETOLOGIA, 2013, 56 : S355 - S355
  • [26] Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin
    Barnett, Anthony H.
    Charbonnel, Bernard
    Donovan, Mark
    Fleming, Douglas
    Chen, Roland
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (04) : 513 - 523
  • [27] Insulin degludec/liraglutide (IDegLira) improves patient-reported outcomes in subjects with type 2 diabetes uncontrolled on insulin glargine plus metformin: DUALV
    Lingvay, I.
    Manghi, F. C. Perez
    Garcia-Hernandez, P. A.
    Norwood, P.
    Jarlov, H.
    Kongso, J. H.
    Brod, M.
    DIABETOLOGIA, 2015, 58 : S400 - S400
  • [28] Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
    von Websky, Karoline
    Reichetzeder, Christoph
    Hocher, Berthold
    VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 : 681 - 694
  • [29] Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes
    Luo, Qiong
    Zhou, Li
    Zhou, Naitong
    Hu, Ming
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [30] A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients
    Pala, L.
    Mannucci, E.
    Dicembrini, I.
    Rotella, C. M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 78 (01) : 132 - 135
12345